Mi­tra Biotech to fo­cus on Nex­tGen Cancer Im­munother­a­pies

BioSpectrum (India) - - COMPANY NEWS -

Mi­tra Biotech has re­cently an­nounced a col­lab­o­ra­tive re­search part­ner­ship with Brigham and Women’s Hos­pi­tal and the De­part­ment of Neu­ro­surgery to fur­ther trans­form per­son­al­ized im­muno-on­col­ogy drug de­vel­op­ment. The agree­ment, with Dr Sean Lawler, As­sis­tant Pro­fes­sor of Medicine and Man­ag­ing Di­rec­tor of the

Har­vey Cush­ing Neuro-on­col­ogy Lab­o­ra­to­ries at the Brigham, is to eval­u­ate on­colytic viruses that have been de­vel­oped in the De­part­ment of Neu­ro­surgery at the hos­pi­tal. These novel en­gi­neered ver­sions of the Her­pes Sim­plex Virus 1 (HSV1), which have been ex­ten­sively char­ac­ter­ized pre-clin­i­cally, are ca­pa­ble of se­lec­tive in­fec­tion and repli­ca­tion within tu­mor cells, and can stim­u­late the im­mune sys­tem. Clin­i­cal tri­als are now un­der­way at the Brigham to in­ves­ti­gate on­colytic viruses in pa­tients with the ag­gres­sive and in­cur­able brain tu­mor glioblas­toma mul­ti­forme (GBM).

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.